The Tough Tech problem we are solving
Harton Therapeutics is addressing the reality that progress in medicine increasingly depends on access to large quantities of high-quality human cells, yet legacy manufacturing systems struggle to preserve biological fidelity while scaling to every patient in need. Rather than incrementally automating older approaches, Harton is building a new, biology-first foundation for human cell manufacturing to improve consistency, reduce cost per patient, and expand global access to life-changing cell therapies.
About our solution
Harton’s HT‑1 platform is a GMP‑ready, benchtop, fully automated system that delivers biology-first, full-stack cell manufacturing inside a closed, single-use cartridge that integrates perfused 3D culture with all key unit operations. Powered by the Solid-State Bioprocessor, HT‑1 provides a structured 3D microenvironment with controlled microforces and enhanced signaling, enabling multi-billion-cell yields with high viability and consistent functional phenotype from research through commercial manufacturing, while reducing reagent consumption and operational complexity.